With a market capitalization (market cap) of $1.36B — a measure of how much the company is worth — Lycia Therapeutics Inc. ranks #2,288 among the 2,496 companies tracked, and 318th in Healthcare as of October 28, 2026. Shares trade at $26.11, down 9.50% on the day.
of 2,496 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 23, 2026. Ranking headline cap is the snapshot figure as of October 28, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 23, 2026 | $1.56B | — | $30.00 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.36B as of October 28, 2026.
Lycia Therapeutics Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $26.11 as of October 27, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.56B on October 23, 2026. See how the ranking works.
The ranking snapshot ($1.36B as of October 28, 2026) is FMP company-screener market cap. The historical observation ($1.56B on October 23, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
Book equity: assets minus liabilities on the latest annual report.
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Not in this snapshot
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.21T | +0.22% |
| #20 | Johnson & Johnson JNJ | $646.92B | +0.91% |
| #23 |
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Summary from the company profile (Financial Modeling Prep).
Visit websiteAs of October 28, 2026, Lycia Therapeutics Inc. (LYCA) is worth $1.36B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. Book equity is blank on this page when annual book value per share is missing. Market cap is the market value of the outstanding shares. As of October 28, 2026, its market cap is $1.36B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Lycia Therapeutics Inc. ranks #2,288 among the 2,496 companies tracked on MarketCapLens. In Healthcare it ranks #318 of 358.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Not in this snapshot
Too little price history
Not in this snapshot
Not in this snapshot
| $506.17B |
| -0.10% |
| #32 | UnitedHealth Group Incorporated UNH | $368.36B | -0.08% |
| #34 | Merck & Co., Inc. MRK | $349.89B | +0.86% |
| #44 | Novartis AG NVS | $298.15B | +1.98% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2285 | GH Research PLC GHRS | $1.37B | +4.38% |
| #2286 | Empire State Realty OP, L.P. OGCP | $1.37B | -0.91% |
| #2287 | Del Monte Corporation DMC | $1.36B | -1.62% |
| #2289 | Keel Infrastructure Corp. KEEL | $1.36B | +3.21% |
| #2290 | WeRide Inc. WRD | $1.36B | +4.55% |
| #2291 | First Mid Bancshares, Inc. FMBH | $1.36B | -0.20% |
Lycia Therapeutics Inc.’s ranking market cap of $1.36B comes from the same snapshot as the rest of this site, as of October 28, 2026. It is not share price multiplied by the latest fiscal-year weighted-average share count. The ranking snapshot ($1.36B as of October 28, 2026) is FMP company-screener market cap. The historical observation ($1.56B on October 23, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Lycia Therapeutics Inc. (LYCA) shares trade at $26.11, down 9.50% on the day, as of October 28, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.